Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Access to Care for Individuals With Sickle Cell Anemia – SCDAASickle cell disease (SCD) is a genetic b...
-
Ron Brathwaite, MDDr. Brathwaite graduated from the Univer...
-
A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)Limited evidence guides opioid dosing st...
-
Nationwide Children’s HospitalThe Comprehensive Sickle Cell and Thalas...
-
Onyinye Onyekwere, MDDr. Onyinye Onyekwere is a pediatric hem...
-
University of Pittsburgh Medical CenterPeople with inherited blood disorders re...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
